Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Healthtrust
Queensland Health
McKinsey
Accenture
Cipla
Cerilliant
AstraZeneca
McKesson

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,079,248

« Back to Dashboard

Title: Anti-arrhythmic agents
Abstract:A series of [N-alkyl-N-(nitro-, alkylsulphonamido, or amino-phenalkyl) amino]-alkyl, alkoxy or alkylthio phenyl derivatives having utility as anti-arrhythmic agents.
Inventor(s): Cross; Peter E. (Canterbury, GB2), Thomas; Geoffrey N. (Sandwich, GB2), Arrowsmith; John E. (Keal, GB2)
Assignee: Pfizer Inc. (New York, NY)
Filing Date:Jun 20, 1990
Application Number:07/541,232
Claims:1. A compound of the formula: ##STR74## or a pharmaceutically acceptable salt thereof: wherein R.sup.a is --NO.sub.2, --NH.sub.2 or NHSO.sub.2 R.sup.1 where R.sup.1 is a C.sub.1 -C.sub.4 alkyl group;

R.sup.b is --NO.sub.2, --NH.sub.2 or R.sup.3 where R.sup.3 is --NHSO.sub.2 (C.sub.1 -C.sub.4 alkyl) or --CONR.sup.4 R.sup.5 where R.sup.4 and R.sup.5 are each independently H or C.sub.1 -C.sub.4 alkyl or together with the nitrogen atom to which they are attached represent a 1-pyrrolidinyl, piperidino, morpholino or N-methylpiperazin-1-yl group;

With the proviso that when one of R.sup.a and R.sup.b is --NO.sub.2, then the other is not --NH.sub.2 ;

Y is an ethylene group optionally substituted by a methyl group;

"alk" is an ethylene, trimethylene, or tetramethylene group, "alk" being optionally substituted by a methyl group;

R is C.sub.1 -C.sub.4 alkyl; and

R.sup.2 is H, halo, CF.sub.3 or C.sub.1 -C.sub.4 alkyl.

2. A compound of the formula: ##STR75## or a pharmaceutically acceptable salt thereof; wherein R.sup.a is --NO.sub.2, --NH.sub.2 or --NHSO.sub.2 R.sup.1 where R.sup.1 is a C.sub.1 -C.sub.4 alkyl group;

R.sup.b is --NO.sub.2, --NH.sub.2 or R.sup.3 where R.sup.3 is --NHSO.sub.2 (C.sub.1 -C.sub.4 alkyl) or --CONR.sup.4 R.sup.5 where R.sup.4 and R.sup.5 are each independently H or C.sub.1 -C.sub.4 alkyl or together with the nitrogen atom to which they are attached represent a 1-pyrrolidinyl, piperidino, morpholino or N-methylpiperazin-1-yl group;

with the proviso that when one of R.sup.a and R.sup.b is --NO.sub.2, then the other is not --NH.sub.2 ;

Y is an ethylene group optionally substituted by a methyl group;

"alk" is an ethylene, trimethylene or tetramethylene group, "alk" being optionally substituted by a methyl group;

R is C.sub.1 -C.sub.4 alkyl; and

R.sup.2 is H, halo, CF.sub.3 or C.sub.1 -C.sub.4 alkyl.

3. A compound of the formula ##STR76## or a pharmaceutically acceptable salt thereof; where R and R.sup.1 are each independently C.sub.1 -C.sub.4 alkyl;

Y is an ethylene group optionally substituted by a methyl group;

"alk" is an ethylene, trimethylene and tetramethylene group, "alk" being optionally substituted by a methyl group;

R.sup.2 is H, halo, CF.sub.3 or C.sub.1 -C.sub.4 alkyl; and R.sup.3 is a group of the formula --NHSO.sub.2 (C.sub.1 -C.sub.4 alkyl) or --CONR.sup.4 R.sup.5 where R.sup.4 and R.sup.5 are each independently H or C.sub.1 -C.sub.4 alkyl or together with the nitrogen atom to which they are attached represent a 1-pyrroliinyl, piperidino, morpholino or N-methylpiperazin-1-yl group.

4. A compound of the formula: ##STR77##

5. A compound according to claim 2 wherein R is methyl or ethyl.

6. A compound according to claim 5 wherein Y is --(CH.sub.2).sub.2 --.

7. A compound according to claim 3 wherein R is ethyl.

8. A compound according to claim 7 wherein R.sup.2 is H, Cl or CH.sub.3.

9. A compound according to claim 7 wherein R.sup.2 is H, Cl or CH.sub.3.

10. A compound according to claim 7 wherein R.sup.2 is H, Cl or CH.sub.3.

11. A pharmaceutical composition comprising an anti-arrhythmic effective amount of a compound of claim 2 in combination with a pharmaceutically acceptable diluent or carrier.

12. A method of treating cardiac arrhythmia comprising administering to an arrhythmic host in need of such treatment an anti-arrhythmic effective dose of a compound of claim 2 in combination with a pharmaceutically acceptable diluent or carrier.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Julphar
Cantor Fitzgerald
Colorcon
UBS
Argus Health
McKinsey
Accenture
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.